Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO)
ALX Oncology(ALXO.US) Officer Buys US$102.34K in Common Stock
$ALX Oncology(ALXO.US)$ Officer GARCIA PETER S purchased 12,000 shares of common stock on Jun 13, 2024 at an average price of $8.5282 for a total value of $102.34K.Source: Announcement What is stateme
Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review
H.C. Wainwright Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $25
H.C. Wainwright analyst Swayampakula Ramakanth maintains $ALX Oncology(ALXO.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of
ALX Oncology(ALXO.US) Officer Sells US$168.65K in Common Stock
$ALX Oncology(ALXO.US)$ Officer Pons Jaume sold 20,000 shares of common stock on Jun 4, 2024 at an average price of $8.4326 for a total value of $168.65K.Source: Announcement What is statement of chan
ALX Oncology Down Over 15%, on Pace for Largest Percent Decrease Since December 2021 -- Data Talk
ALX Oncology Holdings, Inc. (ALXO) is currently at $8.99, down $1.64 or 15.43% --Would be lowest close since Dec. 6, 2023, when it closed at $8.43 --On pace for largest percent decrease since Dec. 1
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
Express News | ALX Oncology Presents First Evorpacept Combination Data With an Antibody-Drug Conjugate From Phase 1 Aspen-07 Clinical Trial in Patients With Advanced Bladder Cancer
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
Express News | Cantor Fitzgerald Reiterates Overweight on ALX Oncology Holdings
ALX Oncology Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/29/2024 — Cantor Fitzgerald Reiterates → Overweight 04/12/2024 — Cantor Fitzgerald Reiterates → Overw
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (Nasdaq: ALXO), an immuno-oncology company developing therapies that block
LifeSci Capital Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $19
LifeSci Capital analyst Sam Slutsky maintains $ALX Oncology(ALXO.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate of 44.8% and a
Buy Rating for ALX Oncology Amid Impressive Evorpacept and Padcev Combination Trial Results
Stifel Maintains ALX Oncology(ALXO.US) With Hold Rating, Maintains Target Price $14
Stifel analyst Bradley Canino maintains $ALX Oncology(ALXO.US)$ with a hold rating, and maintains the target price at $14.According to TipRanks data, the analyst has a success rate of 45.7% and a tota
Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Mirum Pharmaceuticals (MIRM) and IDEAYA Biosciences (IDYA)
Insider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells Shares
No Data